Bms
Bristol Myers Squibb (BMS), a leading biopharmaceutical company headquartered in the United States, has been at the forefront of medical innovation since its founding in 1887. With a strong presence in North America, Europe, and Asia, BMS focuses on discovering, developing, and delivering innovative medicines for serious diseases, particularly in oncology, immunology, and cardiovascular health. BMS is renowned for its core products, including the groundbreaking cancer therapies Opdivo and Yervoy, which have transformed treatment paradigms. The company’s commitment to research and development has positioned it as a market leader, achieving significant milestones such as the successful launch of multiple life-saving therapies. With a robust pipeline and a dedication to patient-centric solutions, Bristol Myers Squibb continues to make a profound impact on global health.
DitchCarbon Score
How does Bms's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bms's score of 71 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bms's reported carbon emissions
In 2023, Bristol Myers Squibb (BMS) reported total carbon emissions of approximately 2,117,929,000 kg CO2e. This includes 208,535,000 kg CO2e from Scope 1 (direct emissions), 158,447,000 kg CO2e from Scope 2 (indirect emissions), and a significant 1,633,858,000 kg CO2e from Scope 3 emissions, which encompass the entire value chain. BMS has set ambitious climate commitments, aiming for net-zero emissions across all scopes (1, 2, and 3) by 2050. In the near term, the company targets a 54.6% reduction in absolute Scope 1 and 2 GHG emissions by 2033, using 2022 as the baseline year. Additionally, BMS plans to reduce absolute Scope 3 emissions from fuel and energy-related activities by the same percentage within the same timeframe. By 2040, BMS aims to achieve net neutrality in Scope 1 and 2 emissions. Furthermore, BMS is committed to ensuring that 75% of its suppliers, based on emissions from purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2028. The company also plans to source 100% of its purchased electricity from renewable sources for its global facilities by 2030. These initiatives reflect BMS's dedication to addressing climate change and reducing its carbon footprint in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 210,540,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 150,790,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 69,630,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 00,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bms is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
